Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, +19

New England Journal of Medicine

Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse

Marco Cecchini, Melissa G. Dominguez, Simonetta Mocci, +7

Development

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters, Scott Gettinger, Melissa L. Johnson, +25

Journal of Clinical Oncology

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, +8

Journal of Clinical Oncology

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Marcin Kowanetz, Wei Zou, Scott Gettinger, +27

Proceedings of the National Academy of Sciences

Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis.

Luigina Romani, Antonella Mencacci, Ursula Grohmann, +4

The Journal of Experimental Medicine

Adaptive Immune SystemImmunodeficienciesImmunologyImmunologic MechanismCd4 T Cell Responses +17

Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance

Luigina Romani, Simonetta Mocci, Carla Bietta, +3

Infection and Immunity

Cd4+ CellsMicrobial PathogensSecretion PatternsTh2 Cd4+Immunology +17

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone, +16

Journal of Thoracic Oncology

MedicinePharmacologyImmune Checkpoint InhibitorPharmacotherapyAnti-cancer Agent +5

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Bharathi Vennapusa, Brian M. Baker, Marcin Kowanetz, +17

Applied immunohistochemistry & molecular morphology

ImmunologyImmunoeditingPathologyImmunotherapyTumor Biology +14

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

David R. Spigel, Filippo de Marinis, Giuseppe Giaccone, +17

Annals of Oncology

Pd-l1–selected NsclcOncologyMedicineImmune Checkpoint InhibitorPharmacotherapy +7